APA Citation

Rosenstock, J., Balas, B., Charbonnel, B., Bolli, G. B., Boldrin, M., Ratner, R., & Balena, R. (2013). The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial. American Diabetes Association.

Chicago Style Citation

Rosenstock, Julio, Bogdan Balas, Bernard Charbonnel, Geremia B. Bolli, Mark Boldrin, Robert Ratner, and Raffaella Balena. The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 Trial. American Diabetes Association, 2013.

MLA Citation

Rosenstock, Julio, et al. The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 Trial. American Diabetes Association, 2013.

Warning: These citations may not always be 100% accurate.